Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity

European Journal of Endocrinology

Volumn 135, Issue 6, 1996, Pages 678-682

  Grottoli, Silvia ^a   Maccario, Mauro ^a   Procopio, Massimo ^a   Oleandri, Salvatore Endrio ^a   Arvat, Emanuela ^a   Gianotti, Laura ^a   Deghenghi, Romano ^b   Camanni, Franco ^a   Ghigo, Ezio ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b Ardana   (France)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GONADORELIN AGONIST; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FLUSHING; GROWTH HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; OBESITY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0030483379     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1350678     Document Type: Article

References (46)

1. Glass AR, Burman KD, Daahms WT, Bohen TM. Endocrine function in human obesity. Metabolism 1981;30:89-104
2. Veldhuis JD, Iranmanesh A, Ho KKY, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991;72:51-9
3. Williams T, Berelowitz M, Joffe SN, Thorner MO, Rivier J, Vale M, et al. Impaired growth hormone responses to growth hormone-releasing factor in obesity. N Engl J Med 1984;311:1403-7
4. Tanaka K, Inoue S, Numata K, Okazaki H, Nakamura S, Takamura Y. Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine and L-dopa in obesity. Metabolism 1990;39:892-6
5. Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F. et al. In obesity the somatotrope response to GHRH or arginine is inhibited by somatostatin or pirenzepine but not by oral glucose load. J Clin Endocrinol Metab 1995;80:3774-8
6. Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after combined administration of GH-releasing hormone and GHRP-6: evidence for marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 1993;76:819-23
7. Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P, et al. The growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. J Clin Endocrinol Metab 1995;80:674-8
8. Bowers CY. A new dimension on the induced release of growth hormone in obese subjects [editorial]. J Clin Endocrinol Metab 1995;76:817-8
9. Cordido F, Penalva A, Peino R, Casanueva FF, Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6 and pyridostigmine in normal and obese subjects. Metabolism 1995;44:745-8
10. Ghigo E, Procopio M, Boffano GM, Arvat E, Valente F, Maccario M, et al. Arginine potentiates but does not restore the blunted GH response to GHRH in obesity. Metabolism 1992;41:560-3
11. Ghigo E, Procopio M, Maccario M, Bellone J, Arvat E, Campana S, et al. Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? Horm Metab Res 1993;25:305-8
12. Kelijman M, Frohman LA. Enhanced growth hormone responsiveness to GHRH releasing hormone after dietary manipulation in obese and non obese subjects. J Endocrinol 1988;128:389-93
13. Cordido F, Dieguez C, Casanueva FF. Effect of central cholinergic enhancement by pyridostigmine on GH secretion elicited by clonidine, arginine or hypoglycemia in normal and obese subjects. J Clin Endocrinol Metab 1990;70:1361-70
14. Melmed S. Insulin suppresses growth hormone secretion in rat pituitary cells. J Clin Invest 1984;73:1425-33
15. Maccario M, Procopio M, Grottoli S, Oleandri SE, Boffano GM, Talliano M, et al. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. Metabolism 1996. In press
16. Lee EJ, Nam SY, Kim KR, Lee HC, CHO JH, Nam MS. et al. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects. J Clin Endocrinol Metab 1995;80:2495-8
17. Bonora E, Moghetti P, Zenere M, Querena M, Tosi F, Corgnati A, et al. Plasma concentrations of growth hormone during hyperglycemic clamp with or without somatostatin infusion in obese subjects. J Clin Endocrinol Metab 1993;70:1732-4
18. Bowers CY. GH releasing peptides. Structure and kinetics. J Pediatr Endocrinol 1993;6:21-31
19. Deghenghi R, Cananzi M, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of hexarelin a new growth hormone releasing peptide in infant and adult rats. Life Sci 1994;54:1321-8
20. 2), a novel GH-releasing peptide, is biologically active in male and female rats. Endocrine 1994;2:691-5
21. Ilson BE, Jorkasky DK, Curnow RT, Stote RM. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab 1989;69:212-4
22. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975-82
23. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R. et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 1994;78:693-8
24. Badger TM, Millard WY, McCormick GF, Bowers CY, Martin JB. The effects of growth hormone (GH)-releasing peptides on GH secretion in perfused pituitary cells of adult male rats. Endocrinology 1984;115:1432-8
25. 2 in rat primary pituitary cell monolayer culture. Endocrinology 1985;116:952-7
26. 2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′, 5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 1989;124:2791-8
27. 2 stimulate GH release through different receptors sites. J Endocrinol 1991;129:11-9
28. Goth MI, Lyons CE, Canny BJ, Thorner MO. Pituitary adenylate cyclase activating polipeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone GH release through distinct pituitary receptors. Endocrinology 1992;130:939-44
29. Codd EE, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989;28:1139-44
30. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the action of the growth hormone-releasing hexapaptide, GHRP. Endocrinology 1991;128:2027-35
31. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942-7
32. Veeraragan K, Sethumadhavan K, Bowers CY. Growth hormone-releasing peptide (GHRP) binding to porcine anteriorpituitary and hypothalamic membranes. Life Sci 1992;50:1149-55
33. Penalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab 1993;76:168-71
34. Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Neuroendocrinological modulation of the growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 1995;61:51-6
35. Maccario M, Arvat E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP, et al. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. Metabolism 1994;44:134-8
36. Berelowitz M, Dudlak D, Frohman LA. Release of somatostatin-like immunoreactivity from incubated rat hypothalamus and cerebral cortex. Effects of glucose and glucoregulatory hormones. J Clin Invest 1982;69:1293-301
37. Penalva A, Burguera B, Casabiell X, Tresguerres JAF, Dieguez C, Casanueva FF. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH)-releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? Neuroendocrinology 1989;49:551-4
38. Delitala G, Tomasi PA, Palermo M, Fresu P. Interaction of glucose and pyridostigmine on the secretion of growth hormone induced by GH-releasing hormone. J Endocrinol Invest 1990;13:653-6
39. Page MD, Kppperschaar PF, Edwards CA, Dieguez C, Scanlon MF. Additive effects of growth hormone releasing factor and insulin hypoglycaemia on growth hormone release in man. Clin Endocrinol 1987;26:589-94
40. Davies RR, Turner S, Johnston DG. Oral glucose inhibits growth hormone secretion induced by human pancreatic growth hormone factor 1-44 in normal man. Clin Endocrinol 1984;21:477-81
41. Masuda A, Shibasaki T, Nakahara M, Imaki T, Kiyisawa T, Jibiki K, et al. The effect of glucose on growth hormone-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab 1985;60:523-6
42. Richardson SB, Hollander GS, D'Eletto RD, Greenleaf PV, Thaw C. Acetilcholine inhibits the release of somatostatin from rat hypothalamus in vitro. Endocrinology 1980;107:1837-41
43. Locatelli V, Torsello A, Redaelli M, Ghigo E, Massara F, Muller EE. Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in rat: evidence for mediation by somatostatin. J Endocrinol 1986; 111:271-8
44. Polosky KS, Given BD, Van Cauter E. 24-hours profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;82:442-8
45. Karam JH, Grodsky GM, Forsham PH. Excessive insulin response to glucose in obese subjects measured by immunochemical assay. Diabetes 1963;12:197-201
46. Grunstein HS, James DE, Storlien LH, Smythe GA, Kraegen EW. Hyperinsulinemia suppresses glucose utilization in specific brain regions: in vivo studies using the euglycemic clamp in the rat. Endocrinology 1985;116:604-10